波士顿科学公司任命Joseph M. Fitzgerald担任执行副总裁兼首席运营官
波士顿科学公司宣布任命Joseph M. Fitzgerald担任执行副总裁兼首席运营官，自2027年1月1日起生效。公司还将于同一天设立三个新的可报告业务部门——介入治疗、节律解决方案和MedSurg，以支持更快的决策制定和战略投资分配。
为什么重要. 领导层变动和组织结构调整影响波士顿科学的全球运营和战略方向，可能对其在医疗技术市场中的运营效率和增长执行产生影响。
01
影响到谁
- 1Boston Scientific
- 经营于 →事实
- 产出 →事实
- 收购 →事实
- 经营于 →事实
02
证据
- PPR Newswire news releases公司披露2026-10-07 18:00
Rhythm Solutions will include Electrophysiology, WATCHMAN and Cardiac Rhythm Management & Diagnostics
- PPR Newswire news releases公司披露2026-10-07 18:00
Fitzgerald currently serves as executive vice president and group president, Cardiovascular, Boston Scientific.
- PPR Newswire news releases公司披露2026-10-07 18:00
Boston Scientific Corporation (NYSE: BSX) today announced the appointment of Joseph M. Fitzgerald to executive vice president and chief operating officer (COO), effective Jan. 1, 2027.
- PPR Newswire news releases公司披露2026-10-07 18:00
As a global medical technology leader for more than 45 years
- PPR Newswire news releases公司披露2026-10-07 18:00
MedSurg will include Endoscopy, Urology and Neuromodulation.
- PPR Newswire news releases公司披露2026-10-07 18:00
Interventional Therapies will include the Interventional Cardiology, Vascular Therapies and Interventional Oncology & Embolization businesses
- PPR Newswire news releases公司披露2026-10-07 18:00
In connection with Fitzgerald's appointment, Boston Scientific will establish three reportable segments* — Interventional Therapies, Rhythm Solutions and MedSurg also effective Jan. 1. As the company continues to grow and expand its portfolio, the structure is designed to enable…
- PPR Newswire news releases公司披露2026-10-07 18:00
MARLBOROUGH, Mass., Oct. 7, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the appointment of Joseph M. Fitzgerald to executive vice president and chief operating officer (COO), effective Jan. 1, 2027.
- MMedTech Dive媒体2026-10-08 18:55